PEMPHIGUS
Pemphigus - From autoimmunity to disease
| Coordinatore | PHILIPPS UNIVERSITAET MARBURG
Organization address
address: Biegenstrasse 10 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.pemphigus.eu |
| Totale costo | 3˙693˙527 € |
| EC contributo | 2˙819˙400 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-05-01 - 2011-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
PHILIPPS UNIVERSITAET MARBURG
Organization address
address: Biegenstrasse 10 contact info |
DE (MARBURG) | coordinator | 0.00 |
| 2 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 0.00 |
| 3 |
FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA
Organization address
address: Via Vincenzo Vela 6 contact info |
CH (BELLINZONA) | participant | 0.00 |
| 4 |
PROVINCIA ITALIANA DELLA CONGREGAZIONE DEI FIGLI DELLA IMMACOLATA CONCEZIONE
Organization address
address: VIA DELLA LUCE 46 contact info |
IT (ROMA) | participant | 0.00 |
| 5 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | participant | 0.00 |
| 6 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 0.00 |
| 7 |
UNIVERSITE DE ROUEN
Organization address
address: RUE THOMAS BECKET 1 MONT SAINT AIGNAN contact info |
FR (MONT SAINT AIGNAN CEDEX) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Pemphigus is a potentially lethal bullous disease of the skin and mucosa and may be considered as a paradigmatic organ-specific autoimmune disease due to 1) its well-defined autoantigens, 2) the knowledge of critical events of its immune pathogenesis and 3) the reproducibility of major clinical and pathogenic features in suitable animal models. Overall, understanding the etiopathogenesis of pemphigus may provide crucial additional insight into basic mechanisms leading from autoimmunity to autoimmune disease and may help to design more specific therapeutic strategies. Despite the enormous progress, no specific therapy is currently available in pemphigus. The present project arises as a joined effort of European Scientists and Clinicians to establish a Consortium of groups engaged in providing a critical mass of patients and research tools to address the following goals: 1) to better define the immune pathogenesis of pemphigus utilizing two in vivo models of pemphigus with emphasis on autoaggressive T cells and their collaboration with autoantibody (autoAb) secreting B cells. 2) analysis of the autoAb-driven effector phase frequently involving “epitope spreading” which ultimately leads to a more severe disease; 3) characterization of the molecular events following Ab binding to the target autoantigens by defining autoAb-induced signalling events in epidermal keratinocytes; 4) spectrum of the autoimmune B cell response and the impact of therapeutic strategies on the cellular and humoral autoimmune response in pemphigus utilizing human monoclonal Ab which will be analysed for their fine specificity and genetically and functionally characterized; and 5) clinical read-out parameters for prospective studies which are urgently needed as valid parameters for the extent and activity of disease and which will be compared to serological markers and life quality assessment in pemphigus.'